Ocuphire Pharma Results Presentation Deck
4
Ocuphire Pipeline & Upcoming Milestones
Multiple Phase 3 & Phase 2 Clinical Data Readouts Anticipated Over the Next Year
Ocuphire-Focused Development
Partnering-
Focused
Development
Product Candidate
0.75% NyxolⓇ
Eye Drop
0.75% NyxolⓇ
Eye Drop
0.75% Nyxol® + Low-Dose
0.4% Pilocarpine Eye Drops
APX3330
Oral Pill
APX2009 Intravitreal
Combo (0.75% NyxolⓇ
+ Latanoprost)
Eye Drops
Indication
Dim Light or Night Vision
Disturbances (NVD)
Reversal of Mydriasis (RM)
Presbyopia (P)
Diabetic Retinopathy (DR)/ Macular
Edema (DME)
DME, Wet Age-Related Macular
Degeneration (wAMD)
Glaucoma
(16 to 24 mmHg)
Pre-clinical
Development Stage
Phase 1
Phase 2
Phase 3
Enrollment Complete/Data Readout
Anticipated Milestones
Initiated Phase 3 LYNX-1 trial 4Q2020;
Data expected in 3Q21 (n=160)
Initiated Phase 3 MIRA-2 trial 4Q2020;
Topline data reported in 1Q21 (n=185)
Initiated Phase 2 VEGA-1 trial 1Q2021;
Data expected in 2Q21 (n=152)
Initiate Phase 2 ZETA-1 trial 1Q2021;
Data expected by early 2022 (n=100)
Next steps: IND enabling studies
(with partner funding)
Next steps: 2nd line add-on Phase 2
trial (with partner funding)
Note: 0.75% Nyxol (Phentolamine Ophthalmic Solution) is the same as 1% Nyxol (Phentolamine Mesylate Ophthalmic Solution)
Ocuphire
PHARMAView entire presentation